340binformed.org

Your Free Source for 340B News and Commentary

  • About us
  • Advertise
  • Contact
  • 340B Health

Lilly Limits Zyprexa Sales as 340B Price Falls to a Penny

Allocation system is the first since OPA issued policy clarification in November
 

Print Article

April 4, 2012—Drug manufacturer Eli Lilly and Co. is limiting sales of its widely used atypical antipsychotic Zyprexa (olanzapine) in light of the drug’s 340B ceiling price falling to $0.01 under the Office of Pharmacy Affairs’ (OPA) “penny pricing” policy.

The company notified OPA that it was instituting the purchasing limits in a March 28 letter that OPA posted on its home page on April 2. It marks the first time that a manufacturer has announced an allocation system for one of its products since OPA clarified its penny-pricing policy last November. 


You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register.    Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)

 

FOLLOW | SHARE | LIKE

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

340B Health Twitter

Twitter feed is not available at the moment.

RSS 340B Employed

  • Pharmacist - 340B Coordinator - Hybrid | Cedars Sinai June 27, 2025
  • Compliance Analyst, 340B Program ( On-Site ) | WMCHealth June 27, 2025
  • Manager, 340B Program ( On-Site ) | WMCHealth June 27, 2025
  • 340B Program Compliance Analyst | UNC Health June 27, 2025
  • 340B Program Coordinator Pharmacy Technician | Northern Arizona Helathcare June 9, 2025

Copyright © 2025 · 340B Health